Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143175 | 0.81 | ALDH1A1 (0.54) | EP300KAT2BF10MEN1KMT2A | |
| SCHEMBL31381708 | 0.80 | COMT (0.46) | CA12CA1CA2CA9CA14 | |
| SCHEMBL9110239 | 0.79 | HTT (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL30080798 | 0.79 | HTT (0.55) | CA12CA1CA2CA9CA14 | |
| SCHEMBL9110780 | 0.79 | CA12 (0.44) | CA12CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL30385194 | 0.78 | HTT (0.53) | CA12CA1CA2CA9CA14 | |
| SCHEMBL20538384 | 0.77 | CYP3A4 (0.61) | LMNAMEN1KMT2ACYP1A2MAPT | |
| SCHEMBL13284150 | 0.77 | LMNA (0.43) | CA12CA9CA14BCHELMNA | |
| SCHEMBL2645575 | 0.76 | DDB1 (0.41) | CA12CA1CA2CA9CA14 | |
| SCHEMBL31134309 | 0.75 | CA12 (0.41) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117241800-A | Antiviral Activity of VPS34 inhibitors | 德西费拉制药有限责任公司 | 2023-12-15 | — | — | CN | claimed |
| EP-4125891-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Aclaris Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| EP-2648516-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | Confluence Life Sciences, Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| WO-2012078684-A1 | SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| EP-0994873-A1 | SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABA A?ALPHA 2/3 LIGANDS | MERCK SHARP & DOHME LTD. (GB) | 2000-04-26 | — | — | EP | claimed |
| WO-1998055480-A1 | SUBSTITUTED 1H-PYRIDINYL-2-ONES AS GABAAALPHA 2/3 LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1998-12-10 | — | — | WO | claimed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | ACLARIS THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| CN-119454711-A | Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025006568-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-115484952-B | Methods, compositions and crystalline forms of substituted pyridone-pyridinyl compounds | 阿克拉瑞斯治疗股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118510776-A | Five-membered ring-containing derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-7612089-B2 | Tetrahydroisoquinolines as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063113-A2 | UREAS AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| WO-2006055951-A2 | TETRAHYDROISOQUINOLINES AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1506186-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003099808-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | CA12 2924/4885CA1 2854/4885CA2 1573/4885 |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | TFPI, F12, F11 | CA12 933/4885CA1 351/4885CA2 1278/4885 |
| US-20060160840-A1 | N-[4-(1-methyl-4,5-dihydro-1H-imidazol-2-yl)phenyl]-2N-(4-chlorophenylaminocarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide; thrombosis; inhibits coagulation of a blood sample | TFPI, F2, TFPI2 | CA12 793/4885CA1 204/4885CA2 458/4885 |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | MALT1, SSB, BCL9 | CA12 2565/4885CA1 1709/4885CA2 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.